{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T03:32:18Z","timestamp":1762918338457,"version":"3.45.0"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T00:00:00Z","timestamp":1656460800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine: X"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.jvacx.2022.100190","type":"journal-article","created":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T12:10:24Z","timestamp":1656763824000},"page":"100190","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Antibody persistence following administration of a hexavalent DTwP-IPV-HB-PRP\u223cT vaccine versus separate DTwP-HB-PRP\u223cT and IPV vaccines at 12\u201324\u00a0months of age and safety and immunogenicity of a booster dose of DTwP-IPV-HB-PRP\u223cT in healthy infants in India"],"prefix":"10.1016","volume":"11","author":[{"given":"S","family":"Mangarule","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Palkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Mitra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MD","family":"Ravi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Moureau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MV","family":"Jayanth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"DM","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Ravinuthala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"BN","family":"Patnaik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Jordanov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Noriega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jvacx.2022.100190_b0005","series-title":"Vaccines","first-page":"198","article-title":"Combination vaccines","author":"Decker","year":"2018"},{"key":"10.1016\/j.jvacx.2022.100190_b0010","unstructured":"Indian Academy of Pediatrics. IAP immunization timetable 2014: IAP recommended vaccines for routine use. Available from: https:\/\/immunizeindia.org\/files\/immschedule.pdf. Accessed 9 February 2022."},{"key":"10.1016\/j.jvacx.2022.100190_b0015","unstructured":"Global Polio Eradication Inititative. The polio endgame strategy 2019-2023: eradication, integration, containment and certification. Available from: polioeradication.org\/who-we-are\/polio-endgame-strategy-2019-2023\/. Accessed 19 January 2022."},{"issue":"9","key":"10.1016\/j.jvacx.2022.100190_b0020","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.4161\/hv.25407","article-title":"Hexavalent IPV-based combination vaccines for public-sector markets of low-resource countries","volume":"9","author":"Mahmood","year":"2013","journal-title":"Human Vaccines & Immunother"},{"issue":"7","key":"10.1016\/j.jvacx.2022.100190_b0025","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1586\/erv.11.72","article-title":"A DTaP-IPV\/\/PRP\u223cT vaccine (Pentaxim): a review of 16 years' clinical experience","volume":"10","author":"Plotkin","year":"2011","journal-title":"Expert Rev Vaccines"},{"issue":"5","key":"10.1016\/j.jvacx.2022.100190_b0030","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s40272-019-00353-7","article-title":"DTaP-IPV-HepB-Hib vaccine (Hexyon\u00ae): an updated review of its use in primary and booster vaccination","volume":"21","author":"Syed","year":"2019","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.jvacx.2022.100190_b0035","doi-asserted-by":"crossref","unstructured":"Mangarule S, Palkar S, Mitra M, Ravi MD, Dubey AP, Moureau A, et al. Safety and immunogenicity of a hexavalent DTwP-IPV-HB-PRP\u223cT vaccine versus separate DTwP-HB-PRP\u223cT and IPV vaccines in healthy infants in India. Vaccine X. 2022;10:https:\/\/doi.org\/10.1016\/j.jvacx.2021.100137.","DOI":"10.1016\/j.jvacx.2021.100137"},{"issue":"37","key":"10.1016\/j.jvacx.2022.100190_b0040","doi-asserted-by":"crossref","first-page":"5600","DOI":"10.1016\/j.vaccine.2018.07.048","article-title":"Development and application of a multiplex assay for the simultaneous measurement of antibody responses elicited by common childhood vaccines","volume":"36","author":"Itell","year":"2018","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.jvacx.2022.100190_b0045","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0092-1157(83)80031-6","article-title":"Poliovirus and polio antibody assay in HEp-2 and Vero cell cultures","volume":"11","author":"Albrecht","year":"1983","journal-title":"J Biol Stand"},{"key":"10.1016\/j.jvacx.2022.100190_b0050","unstructured":"WHO. Guidelines for WHO\/EPI collaborative studies on poliomyelitis: standard procedure for determining immunity to poliovirus using the microneutralization test. Available from: https:\/\/apps.who.int\/iris\/handle\/10665\/70486. Accessed 9 February 2022."},{"issue":"8","key":"10.1016\/j.jvacx.2022.100190_b0055","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E","article-title":"Two-sided confidence intervals for the single proportion: comparison of seven methods","volume":"17","author":"Newcombe","year":"1998","journal-title":"Stat Med"},{"key":"10.1016\/j.jvacx.2022.100190_b0060","doi-asserted-by":"crossref","unstructured":"Gunardi H, Rusmil K, Fadlyana E, Soedjatmiko, Dhamayanti M, Sekartini R, et al. DTwP-HB-Hib: antibody persistence after a primary series, immune response and safety after a booster dose in children 18-24 months old. BMC Pediatr. 2018;18(1):177.","DOI":"10.1186\/s12887-018-1143-6"},{"issue":"3","key":"10.1016\/j.jvacx.2022.100190_b0065","doi-asserted-by":"crossref","first-page":"347","DOI":"10.4161\/hv.18630","volume":"8","author":"Quiambao","year":"2012","journal-title":"Human Vaccines & Immunother"},{"issue":"3","key":"10.1016\/j.jvacx.2022.100190_b0070","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.vaccine.2012.11.038","article-title":"Antibody persistence of two pentavalent DTwP-HB-Hib vaccines to the age of 15\u201318 months, and response to the booster dose of quadrivalent DTwP-Hib vaccine","volume":"31","author":"Sharma","year":"2013","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.jvacx.2022.100190_b0075","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.vaccine.2011.11.067","article-title":"Assessment of safety and immunogenicity of two different lots of diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae type b vaccine manufactured using small and large scale manufacturing process","volume":"30","author":"Sharma","year":"2012","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.jvacx.2022.100190_b0080","doi-asserted-by":"crossref","first-page":"451","DOI":"10.4161\/hv.7.4.14208","article-title":"Immunogenicity and safety of an indigenously manufactured reconstituted pentavalent (DTwP-HBV+Hib) vaccine in comparison with a foreign competitor following primary and booster immunization in Indian children","volume":"7","author":"Sharma","year":"2011","journal-title":"Human Vaccines"},{"issue":"8","key":"10.1016\/j.jvacx.2022.100190_b0085","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1097\/INF.0b013e318292f7b1","article-title":"Antibody persistence and booster vaccination of a fully liquid hexavalent vaccine coadministered with measles\/mumps\/rubella and varicella vaccines at 15\u201318 months of age in healthy South African infants","volume":"32","author":"Madhi","year":"2013","journal-title":"Pediatr Infect Dis J"},{"issue":"10","key":"10.1016\/j.jvacx.2022.100190_b0090","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s13312-012-0191-5","article-title":"Immunogenicity and safety of a DTaP-IPV\/\/PRP\u223cT vaccine (Pentaxim) booster dose during the second year of life in Indian children primed with the same vaccine","volume":"49","author":"Dutta","year":"2012","journal-title":"Indian Pediatr"},{"key":"10.1016\/j.jvacx.2022.100190_b0095","doi-asserted-by":"crossref","DOI":"10.1007\/s40121-021-00530-7","article-title":"A new electrochemiluminescence-based multiplex assay for the assessment of human antibody responses to Bordetella pertussis vaccines","author":"Varghese","year":"2021","journal-title":"Infectious Dis Ther"}],"container-title":["Vaccine: X"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S259013622200050X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S259013622200050X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T02:08:38Z","timestamp":1762913318000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S259013622200050X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":19,"alternative-id":["S259013622200050X"],"URL":"https:\/\/doi.org\/10.1016\/j.jvacx.2022.100190","relation":{},"ISSN":["2590-1362"],"issn-type":[{"type":"print","value":"2590-1362"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibody persistence following administration of a hexavalent DTwP-IPV-HB-PRP\u223cT vaccine versus separate DTwP-HB-PRP\u223cT and IPV vaccines at 12\u201324\u00a0months of age and safety and immunogenicity of a booster dose of DTwP-IPV-HB-PRP\u223cT in healthy infants in India","name":"articletitle","label":"Article Title"},{"value":"Vaccine: X","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvacx.2022.100190","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100190"}}